Pathologic Responses to Stereotactic Ablative Radiotherapy in Combination With Nivolumab for Early Stage NSCLC: A Phase 2 Study
The neoadjuvant combination of three doses of nivolumab and SABR produced a high pCR rate in stage I NSCLC. Further research is warranted to evaluate this treatment modality in patients with medically inoperable NSCLC and whether surgery could be safely omitted for patients who are candidates for resection.
Authors
- Ana Carolina Pires de Rezende (ORCID: https://orcid.org/0000-0002-7401-9033)
- Patrícia Severino (ORCID: https://orcid.org/0000-0002-6682-9343)
- Paulo Vidal Campregher (ORCID: https://orcid.org/0000-0001-6005-405X)
- José Milanez Ribas
- Luciana Cavalheiro Marti (ORCID: https://orcid.org/0000-0002-3890-0827)
- Vítor Ribeiro Paes (ORCID: https://orcid.org/0000-0001-8752-5624)
- Ricardo Mingarini Terra (ORCID: https://orcid.org/0000-0001-8577-8708)
- Vítor Sousa (ORCID: https://orcid.org/0000-0003-3219-1078)
- Gustavo Schvartsman (ORCID: https://orcid.org/0000-0001-6601-3726)
- Patrícia Taranto (ORCID: https://orcid.org/0000-0002-5199-6085)
- Laura Leaden
- Frederico Monfardini (ORCID: https://orcid.org/0000-0002-9590-5448)
- Benoit Jacques Bibas (ORCID: https://orcid.org/0000-0002-5092-0505)
- Marcos Naoyuki Samano (ORCID: https://orcid.org/0000-0002-0602-0569)
- Rodrigo Caruso Chate (ORCID: https://orcid.org/0000-0002-4193-7647)
- Fernando Moura (ORCID: https://orcid.org/0000-0003-1967-1544)
- Diogo Bugano Diniz Gomes
- Ludmila Muniz Koch
- O. Gomes
- Gustavo Prado dos Santos
- Yasmin M. Amirato
Institutions
- Hospital Israelita Albert Einstein (BR)
- Instituto do Câncer do Estado de São Paulo (BR)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100940
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00